Risk of Death in Patients Hospitalized for COVID-19 vs Seasonal Influenza in Fall-Winter 2022-2023

Choi, Taeyoung; Al‐Aly, Ziyad

doi:10.1001/jama.2023.5348

Cited by 63 publications

(30 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, these data are consistent with other studies comparing the clinical course of COVID-19 and influenza. 29–31…”

Section: Discussionmentioning

confidence: 99%

“…Previous analysis of the CDC data has found that the annual COVID-19-associated hospitalization rate during 2020-2021 was higher among children <18 years of age than the influenza-associated hospitalization rate during the prior three seasons. 28 [29][30][31] Like influenza, the incidence of COVID-19 correlates with the arrival of new variants that evade existing immunity; 32,33 however, the arrival and transmission of new COVID-19 variants does not have an established seasonality. Therefore, it is important to acknowledge that although this study is looking at infections during a period that included the peak influenza activity, COVID-19 diagnoses were still more frequent than influenza diagnoses, particularly among hospitalized patients.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Comparison of COVID-19 and Influenza-Related Outcomes in the United States during Fall-Winter 2022-2023

Kopel,

Bogdanov,

Winer-Jones

et al. 2023

Preprint

View full text Add to dashboard Cite

BackgroundThree years into the pandemic, SARS-COV-2 remains a significant burden in comparison to other respiratory illnesses; however, many of the monitoring tools available during the early phase of the COVID-19 pandemic have been phased out, making it more difficult to track the current burden of outpatient medical encounters and hospitalizations, especially for at-risk groups. The objective of this analysis was to characterize the frequency and severity of medically-attended COVID-19 and influenza during peak influenza activity in the pediatric (0-17), adult (18-64), and older adult (65+) populations and characterize the prevalence of underlying medical conditions among patients hospitalized with COVID-19.MethodsThis was a cross-sectional analysis of individuals in the Veradigm Health Insights EHR Database linked to Komodo claims data with a medical encounter of claim between October 1, 2022, and March 31, 2023. We captured age, sex, and underlying medical conditions associated with higher risk for severe COVID-19 during a 12-month baseline period. We identified patients with medical encounters with a diagnosis of COVID-19 or influenza between October 1, 2022, and March 31, 2023, and stratified them into 5 mutually exclusive categories based on the highest level of care received with that diagnosis during the season (intensive care unit [ICU] > hospitalization without ICU > emergency department > urgent care > other outpatient).ResultsAmong the 23,526,196 individuals in the dataset, 5.0% had a COVID-19-related medical encounter, and 3.0% had an influenza-related medical encounter during the 6 month observation period. The incidence of hospitalizations with a COVID-19 diagnosis was 4.6 times higher than the incidence of hospitalizations with an influenza diagnosis. Hospitalizations with COVID-19 were higher in all age groups. Nearly all adults hospitalized with COVID-19 had at least one underlying medical condition, but 25.8% of 0-5-year-olds and 18.3% of 6-17-year-olds had no underlying medical conditions.ConclusionsCOVID-19 continues to place a heavy burden on the United States healthcare system and was associated with more medical encounters in all age groups, including hospitalizations, than influenza during a 6-month period that included the 2022-2023 peak influenza activity.

show abstract

“…Moreover, these data are consistent with other studies comparing the clinical course of COVID-19 and influenza. 29–31…”

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Comparison of COVID-19 and Influenza-Related Outcomes in the United States during Fall-Winter 2022-2023

Kopel,

Bogdanov,

Winer-Jones

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…JAMA publishes articles on research methods to advance the types of science that is important for clinical medicine, as well as commentaries and narrative essays to put the science in context. In the list of top-viewed and top-cited articles from 2023, all of these article types are represented: clinical trials and observational research studies in neurology, cardiology, infectious diseases, psychiatry, endocrinology, genetics, trial emulation methods, and more; editorials and commentaries, including a Viewpoint on the crisis of US child mortality rates; a narrative essay “Death by Patient Portal”; and clinical reviews on glioblastoma and other brain cancers, heart failure with preserved ejection fraction, autism spectrum disorder, and surgical site infections …”

Section: Top-viewed and Top-cited Articles From 2023mentioning

confidence: 99%

“…Perhaps unsurprisingly, one of our top-viewed and top-cited articles is the donanemab phase 3 trial, highlighting the interest in novel therapeutics for a devastating condition like Alzheimer disease. COVID-19 remains of interest to JAMA readers, including the long-term sequelae of COVID-19 infection. An article from the National Institutes of Health–funded RECOVER Consortium, “Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection,” was the second most highly cited Original Investigation in 2023 …”

Section: Top-viewed and Top-cited Articles From 2023mentioning

confidence: 99%

2023 Year in Review and What’s Ahead at JAMA

Bibbins-Domingo,

Flanagin,

Christiansen

et al. 2024

JAMA

View full text Add to dashboard Cite

JAMA celebrated its 140-year anniversary in 2023. In reflecting on JAMA's origins and the descriptions of why JAMA was created, 1 one immediately recognizes the founding principles that still inform our priorities today. The earliest references to the creation of JAMA declare 1 : "But we shall spare neither time nor labor to complete such arrangements as will make the JOURNAL an efficient representative of the scientific, social, and ethical interests…," a sentiment that resonates with our current approach at JAMA.In this year-in-review editorial, we report on key metrics for JAMA. Based on the 2023 numbers (Table ), 2-6 JAMA continues to be a global leader in publishing quality clinical research, reviews, and opinion; having high impact, influence, and reach; and using multiple modes of publication. Here we focus on JAMA authors and readers whose work and interests are represented by these metrics, and the new initiatives launched at JAMA to serve authors, readers, and the broader medical and scientific communities.

show abstract

“…A significant challenge persists in accurately distinguishing COVID‐19 from other respiratory infections, given their overlapping symptomatic profiles, except for more frequent gastrointestinal symptoms 4 . Consequently, there is a need to refine identification and isolation protocols for COVID‐19, particularly among immunocompromised populations, not only by the elevated mortality rates observed in these groups but also by the substantial public health ramifications that could arise from premature deisolation 5–7 …”

Section: Introductionmentioning

confidence: 99%

Virological characteristics and the rapid antigen test as deisolation criteria in immunocompromised patients with COVID‐19: A prospective cohort study

Kang,

Kim,

Kim

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

There are limited data supporting current Centers for Disease Control and Prevention guidelines for the isolation period in moderate to severely immunocompromised patients with coronavirus disease 2019 (COVID‐19). Adult COVID‐19 patients who underwent solid organ transplantation (SOT) or received active chemotherapy against hematologic malignancy were enrolled and weekly respiratory samples were collected. Samples with positive genomic real‐time polymerase chain reaction results underwent virus culture and rapid antigen testing (RAT). A total of 65 patients (40 with hematologic malignancy and 25 SOT) were enrolled. The median duration of viable virus shedding was 4 weeks (interquartile range: 3–7). Multivariable analysis revealed that B‐cell depletion (hazard ratio [HR]: 4.76) was associated with prolonged viral shedding, and COVID‐19 vaccination (≥3 doses) was negatively associated with prolonged viral shedding (HR: 0.22). The sensitivity, specificity, positive predictive value, and negative predictive value of RAT for viable virus shedding were 79%, 76%, 74%, and 81%, respectively. The negative predictive value of RAT was only 48% (95% confidence interval [CI]: 33–65) in the samples from those with symptom onset ≤20 days, but it was as high as 92% (95% CI: 85–96) in the samples from those with symptom onset >20 days. About half of immunocompromised COVID‐19 patients shed viable virus for ≥4 weeks from the diagnosis, and virus shedding was prolonged especially in unvaccinated patients with B‐cell‐depleting therapy treatment. RAT beyond 20 days in immunocompromised patients had a relatively high negative predictive value for viable virus shedding.

show abstract

Risk of Death in Patients Hospitalized for COVID-19 vs Seasonal Influenza in Fall-Winter 2022-2023

Abstract: This study uses data from the US Department of Veterans Affairs to assess whether SARS-CoV-2 remains associated with higher risk of death compared with seasonal influenza in fall-winter 2022-2023.

Cited by 63 publications

References 3 publications

Comparison of COVID-19 and Influenza-Related Outcomes in the United States during Fall-Winter 2022-2023

Comparison of COVID-19 and Influenza-Related Outcomes in the United States during Fall-Winter 2022-2023

2023 Year in Review and What’s Ahead at JAMA

Virological characteristics and the rapid antigen test as deisolation criteria in immunocompromised patients with COVID‐19: A prospective cohort study

Contact Info

Product

Resources

About